Spots Global Cancer Trial Database for Tesetaxel as First-line Therapy for Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Official Title: A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Study ID: NCT01221870
Conditions
Study Description
Brief Summary: The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer. Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
The Moses H. Cone Regional Cancer Center, Greensboro, North Carolina, United States
The West Clinic, Memphis, Tennessee, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Contact Details
Name: Andrew D Seidman, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
